Dosing expected to begin in Q2 2020 with first data in Q3 2020 Trial expected to enroll 224 patients over 12 months, with 24 patients immediately U.S. IND filing planned for later this month ...
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy WALTHAM, Mass., Aug. 29, 2023 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results